Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma

NCT02984410 | Active Not Recruiting DMC

• 1 other identifier: EORTC-1420-HNCG-ROG
• Study Type: interventional
• Target: 112
• Locations: 8 countries
• Sites: 32

Brief Summary

Oropharyngeal Squamous Cell Carcinoma (OPSCC) arises in the soft palate, tonsils, base of tongue, pharyngeal wall, and the vallecula. Most of the patients with early stage OPSCC are usually cured. Treatment of early stage OPSCC can be successfully achieved with primary surgery including neck dissection, as indicated, or with definitive radiotherapy. The current standard treatment for OPSCC is therefore based on either surgery and/or radiotherapy, both associated with comparable, high tumor control rates but with different side effects profiles and technical constraints. In order to decrease the potential morbidity of surgery, transoral approaches have been developed within the last decades, including transoral robotic surgery (TORS), transoral laser microsurgery (TLM) or conventional transoral techniques. On the other hand, patients with head and neck cancer treated with IMRT experienced significant improvements in cause specific survival (CSS) compared with patients treated with non-IMRT techniques thus suggesting that IMRT may be beneficial in terms of patient's outcomes and toxicity profile. It is as yet unclear however, which one of the new techniques is superior to the other in terms of function preservation. Given that the functional outcome of most importance is swallowing function, the preservation of swallowing is thus of major importance. The main objective of the study is to assess and compare the patient-reported swallowing function over the first year after randomization to either IMRT or TOS among patients with early stage OPSCC, SGSCC, and HPSCC.

Conditions

Oropharyngeal Cancer; Supraglottic Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma

Keywords

T1-T2, N0-N1 oropharyngeal carcinoma, supraglottic carcinoma, T1, N0 hypopharyngeal carcinoma

Outcome Measures

Primary Outcomes (1)

• Change in the MD Anderson Dysphagia Inventory (MDADI) score

  at 4.5 and 12 months after randomization

Study Arms (2)

Intensity-Modulated Radiation Therapy (IMRT)

OTHER

PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.

Radiation: Intensity-Modulated Radiation Therapy (IMRT)

Trans Oral Surgery (TOS)

OTHER

The following surgical techniques are allowed: Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)

Procedure: Trans Oral Surgery (TOS)

Interventions

Intensity-Modulated Radiation Therapy (IMRT) RADIATION

IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection

Intensity-Modulated Radiation Therapy (IMRT)

Trans Oral Surgery (TOS) PROCEDURE

TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection

Trans Oral Surgery (TOS)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• OPSCC in one of the following sub-sites: base of tongue, lateral pharyngeal wall, tonsil, glosso-tonsillar sulcus, vallecula or SGSCC in one or more of the following sub-sites: epiglottis, aryepiglottic fold, false cord or HPSCC in one or more of the following subsites: Lateral and medial wall of piriform sinus (sub-sites are defined as lateral (lateral pharyngeal wall, tonsil, glosso-tonsillar sulcus, lateral piriform sinus) vs. central lesions (base of tongue, vallecula, all supraglottic sites, medial wall of piriform sinus))
• TNM stage I-III (7th AJCC classification): T1 or T2, N0 or T1 or T2, N1 with one single neck node ≤ 3cm without radiographic signs of extracapsular extension (ECE), M0;
• TNM stage I for HPSCC: T1, N0, M0. ;
• Within 2 weeks before randomization, assessment by a Multi-Disciplinary Team (MDT) composed of at least a head and neck/ENT surgeon, oncologist, radiologist, radiotherapist, and pathologist of the treatment naïve patient and suitable for either TOS or IMRT based on:
• CT with contrast and/or MRI done within 4 weeks prior to randomization Note: Repeat contrast enhanced CT and/or MRI or US 1 week or less prior to randomization in case of suspicious nodes \<1cm on initial scan if per local practice
• Pan-endoscopy with assessment of trans-oral exposure for resection.
• peri-nodal infiltration either via CT-scan or MRI.
• Age 18 and older; Age 18 to 70 for SGSCC
• ECOG Performance status ≤ 2;
• Availability of biological material for HPV/p16 testing for OPSCCs
• Study information and Informed consent discussed by the surgeon and radio-oncologist and signed by the patient.
• Within 2 weeks prior randomization:
• Baseline MDADI score available;
• Adequate bone marrow function as demonstrated by neutrophils count \> 1,5 109 /L , platelets count \> 75 109 /L, WBC≥ 3.0 109 /L;
• Prothrombin time (PT) with an international normalized ratio (INR) ≤ 1.2

You may not qualify if:

• Any previous anti-cancer therapy for HNSCC (surgery, chemo-, or radiotherapy or molecular targeted therapy);
• Any active malignancy (other than non-melanoma skin cancer or localized cervical cancer or localized and presumed cured prostatic cancer) within the last 5 years with ongoing systemic treatment
• Cancer in contact with the internal and/or common carotid artery
• Extension of OPSCC across the midline of the base-of-tongue
• Arytenoid involvement in case of SGSCC
• Infiltration of apex for piriform sinus in case of HPSCC
• Cancer originating from the soft palate or posterior pharyngeal wall
• Requirement of a reconstruction with a free or regional flap (i.e. involvement of \>50% of the soft palate)
• Pre-existing dysphagia not related to the oropharyngeal cancer or diagnostic biopsies
• Any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol, completion of patient reported measures and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Sponsors & Collaborators

• European Organisation for Research and Treatment of Cancer - EORTC: lead

Study Sites (32)

CHU-UCL Namur - CHU Mont Godinne

Namur, Yvoir, 5530, Belgium

Location

Cliniques Universitaires Saint-Luc

Brussels, Belgium

Location

Institut Jules Bordet-Hopital Universitaire ULB

Brussels, Belgium

Location

U.Z. Leuven - Campus Gasthuisberg

Leuven, Belgium

Location

Hopitaux Universitaires de Strasbourg - Hautepierre

Strasbourg, France

Location

Universitaetsklinikum Koeln

Cologne, Germany

Location

Universitaetklinikum Halle - Martin Luther Universitaet

Halle, 06129, Germany

Location

Universitaets Krankenhaus Eppendorf - UKE - University Cancer Center

Hamburg, Germany

Location

Universitaetsklinikum Jena

Jena, Germany

Location

Staedtisches Klinikum Leipzig - Klinikum St Georg

Leipzig, Germany

Location

Universitaetsklinikum Leipzig

Leipzig, Germany

Location

Klinikum Rechts der isar Der Technische Universitaet Muenchen

München, Germany

Location

Universitaetsklinikum Tuebingen- Crona Kliniken

Tübingen, Germany

Location

Universitaetsklinikum Ulm-Michelsberg-HNO

Ulm, Germany

Location

Istituto Clinico Humanitas

Milan, Italy

Location

Istituto Europeo di Oncologia

Milan, Italy

Location

The Great Poland Cancer Centre

Poznan, Poland

Location

Hospital Universitario Donostia

Barcelona, Spain

Location

Hospital Universitario Ramon y Cajal

Madrid, Spain

Location

Hospital Universitario Central De Asturias

Oviedo, Spain

Location

Universitaetsspital Basel

Basel, Switzerland

Location

Inselspital

Bern, Switzerland

Location

Centre Hospitalier Universitaire Vaudois - Lausanne

Lausanne, Switzerland

Location

UniversitaetsSpital Zurich - Klinik fur Ohren, Hals und Gesichtschirurgie

Zurich, Switzerland

Location

University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre

Bristol, United Kingdom

Location

Cambridge University Hospital NHS - Addenbrookes Hospital

Cambridge, United Kingdom

Location

Cardiff and Vale University Health Board - University Hospital of Wales

Cardiff, United Kingdom

Location

Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital

Cottingham, United Kingdom

Location

Aintree University Hospital NHS Trust

Liverpool, United Kingdom

Location

Guy's and St Thomas' NHS Foundation trust - Guy s and St Thomas' NHS - Guy's Hospital

London, United Kingdom

Location

Imperial College Healthcare NHS Trust - Charing Cross Hospital

London, United Kingdom

Location

South Tees Hospitals NHS Foundation Trust - The James Cook University Hospital

Middlesbrough, United Kingdom

Location

MeSH Terms

Conditions

Oropharyngeal Neoplasms; Squamous Cell Carcinoma of Head and Neck

Interventions

Radiotherapy, Intensity-Modulated

Condition Hierarchy (Ancestors)

Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Neoplasms; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Radiotherapy, Conformal; Radiotherapy, Computer-Assisted; Radiotherapy; Therapeutics

Study Officials

• Christian Simon

  Centre Hospitalier Universitaire Vaudois

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 28, 2016
• First Posted: December 6, 2016
• Study Start: November 27, 2017
• Primary Completion: June 30, 2025
• Study Completion (Estimated): June 30, 2029
• Last Updated: August 14, 2025

Record last verified: 2025-08

Locations

DE (9); PL (1); BE (4); ES (3); GB (8); FR (1); IT (2); CH (4)